# ❤️ CKM Syndrome

**What CKM syndrome actually claims.** Obesity, dysglycemia, chronic kidney disease and cardiovascular disease are not four illnesses that happen to co-occur. They are one pathophysiologic continuum with shared mediators and shared therapeutic targets — and a patient's position along that continuum predicts absolute cardiovascular risk better than counting discrete risk factors.

## 📋 Why the 2026 guideline matters

The staging construct began as the 2023 AHA presidential advisory. The **2026 AHA/ACC/ADA/ASN guideline** converts that advisory into a graded clinical practice guideline with formal COR/LOE recommendations, extends it across the life course, and retires and replaces the 2013 AHA/ACC/TOS obesity guideline.

**For nephrology, one structural fact outranks the rest.** ASN is a full endorsing society alongside ADA and the Obesity Association. CKD is not a downstream complication in this framework — it is a *staging axis of equal standing* with adiposity and dysglycemia, and very-high-risk CKD is treated as a cardiovascular risk equivalent in its own right. Nephrology is embedded in the framework rather than consulted by it.

## 🎯 The five stages at a glance

**Stage 0**No CKM syndrome. Normal weight, glucose, BP, lipids and kidney function; no subclinical or clinical CVD. Primordial prevention. **Stage 1**Excess or dysfunctional adiposity, and/or prediabetes. No other metabolic risk factors, no CKD, no CVD. **Stage 2**Metabolic risk factors and/or CKD — type 2 diabetes, hypertension, hypertriglyceridemia, metabolic syndrome, moderate-to-high-risk CKD. **Stage 3**Subclinical CVD, or a CKM risk equivalent — very-high-risk CKD, or 10-year PREVENT-CVD risk at or above 20%. **Stage 4**Clinical CVD. Substaged 4a (no kidney failure) and 4b (eGFR below 15 or chronic kidney replacement therapy). **Stage 4 is not "any coronary disease."** A coronary calcium score of 900 without events is **stage 3**. A prior PCI is **stage 4** even in a currently asymptomatic patient. The line is clinical events or revascularization — not atherosclerotic burden. Symptomatic heart failure at *any* ejection fraction qualifies, as does atrial fibrillation on its own, with no ischemic or structural disease required.

## 🧠 The one-sentence version

**CKM staging answers "how aggressively do I treat cardiovascular risk, and with which agents?" It does not answer "how fast will this kidney fail?"** Conflating the two is the most common misuse of the framework — and it is why the [CKM versus KFRE](https://urinenephrology.org/2025_UDPA_Lectures_Live/cardiorenal-disease/ckm-vs-kfre.html) deep dive exists.

## 📈 PREVENT — the risk engine underneath

PREVENT estimates 10- and 30-year risk of ASCVD, heart failure and total CVD, and takes eGFR and optionally UACR and HbA1c directly as inputs. It is recommended in stages 0–3; in stage 4 the patient already has clinical disease and prediction is superseded by secondary prevention.

| Threshold | Action |
|----|----|
| PREVENT-CVD 10-year at or above **7.5%** | Prioritize pharmacotherapy |
| PREVENT-CVD 10-year at or above **20%** | Meets a stage 3 criterion as a risk equivalent |
| PREVENT-HF 10-year at or above **5%** in prediabetes or T2D | Obtain natriuretic peptide with or without hs-troponin; image if elevated |

## 💊 Therapy by stage

| Stage | Architecture |
|----|----|
| **1** | Lifestyle as the foundation; obesity pharmacotherapy and metabolic/bariatric surgery as adjuncts, explicitly framed as tools to prevent progression and promote **stage regression**. First guideline to endorse GLP-1-based therapy for cardiovascular event reduction in selected patients with obesity, with or without T2D. |
| **2** | *Metabolic:* GLP-1-based agent or SGLT2 inhibitor with proven benefit when PREVENT-CVD is at or above 7.5%, or age over 50 with added risk factors. Metformin is **adjunctive** — layered onto cardioprotective agents rather than preceding them. *Kidney:* measure eGFR **and** UACR; RASi plus SGLT2i first-line. |
| **3** | Same architecture, intensified. Combination SGLT2i plus GLP-1-based therapy may be considered. Very-high-risk CKD alone qualifies — treat it as a CVD risk equivalent, not a kidney problem awaiting a cardiac indication. |
| **4** | ASCVD plus T2D: at least one agent with proven CV benefit in all patients. HFrEF: RASi (ARNI preferred), beta blocker, steroidal MRA, SGLT2i. HFmrEF/HFpEF: SGLT2i first-line. Obesity and kidney-protective therapy continue in parallel. |

### Persistent albuminuria on first-line therapy

| Add-on | Threshold | Favored when |
|----|----|----|
| **Finerenone** | UACR at or above 30 mg/g | Normokalemic, albuminuria-predominant phenotype |
| **Semaglutide** | UACR at or above 100 mg/g | Obesity, uncontrolled diabetes, or MASLD present |

SGLT2i is the first-line cardioprotective antihyperglycemic in T2D with heart failure or CKD, and is initiable down to **eGFR 20** mL/min/1.73 m².

## 📚 Deep dives

[🧬 Staging and the kidney axis](https://urinenephrology.org/2025_UDPA_Lectures_Live/cardiorenal-disease/ckm-staging-kidney-axis.html) [⚖️ CKM staging vs KFRE](https://urinenephrology.org/2025_UDPA_Lectures_Live/cardiorenal-disease/ckm-vs-kfre.html) [🧪 Glycemic management in CKD](https://urinenephrology.org/2025_UDPA_Lectures_Live/cardiorenal-disease/ckm-glycemic-management.html)

## 🪶 Nephrology-specific traps

### Euglycemic DKA

Relative insulinopenia plus SGLT2i is the classic setup. At HbA1c above 10% with catabolic features, establish insulin before or alongside the SGLT2i.

### eGFR floors

SGLT2i initiation down to eGFR 20 with continuation thereafter. Metformin contraindicated below 30. Finerenone requires potassium surveillance. GLP-1 RA dosing is not eGFR-adjusted.

### Cardiorenal indication is not glycemic control

SGLT2i retains cardiorenal benefit to eGFR 20 but is not a glucose-lowering agent at G4. Do not let the cardiorenal indication substitute for glycemic management.

### Dialysis (stage 4b)

HbA1c has low reliability, pre-HF biomarker cut points are uninterpretable, and PREVENT is not applicable. Three of the framework's instruments go dark at once.

**Where implementation will actually fail.** The guideline's structural recommendations — a named CKM coordination point person, routine social-determinants screening, and selected screening for pre-HF, MASLD and OSA — are the operational core. They are also the parts most health systems will not build.

#### 🔍 Source and verification

Primary source: the **2026 AHA/ACC/ADA/ASN guideline for the prevention, detection, evaluation, and management of cardiovascular-kidney-metabolic syndrome** (Circulation. 2026;154(4):e50–e158, PMID [42263157](https://pubmed.ncbi.nlm.nih.gov/42263157/)), published Free Access and read in full for these pages. Glycemic triggers are from the **ADA Standards of Care in Diabetes — 2026, Section 9** (PMID [41358900](https://pubmed.ncbi.nlm.nih.gov/41358900/)), read in full via PubMed Central. Kidney staging and glycemic targets in CKD are from KDIGO 2024 and KDIGO 2022 (PMID [36272764](https://pubmed.ncbi.nlm.nih.gov/36272764/)), the latter verified against its peer-reviewed synopsis (PMID [36623286](https://pubmed.ncbi.nlm.nih.gov/36623286/)).

**Every numeric threshold on this page was checked against the source text.** Figures that could not be confirmed in a primary source were removed rather than published with a caveat — including a set of pre-HF biomarker cut points that circulate in secondary summaries but appear nowhere in the guideline.

## 📚 Key references

1.  Ndumele CE, Rodriguez F, Dixon DL, et al. 2026 AHA/ACC/ADA/ASN guideline for the prevention, detection, evaluation, and management of cardiovascular-kidney-metabolic syndrome. *Circulation.* 2026;154(4):e50–e158. PMID [42263157](https://pubmed.ncbi.nlm.nih.gov/42263157/).
2.  Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the AHA. *Circulation.* 2023;148(20):1606–1635. PMID [37807924](https://pubmed.ncbi.nlm.nih.gov/37807924/).
3.  Khan SS, Matsushita K, Sang Y, et al. Development and validation of the AHA's PREVENT equations. *Circulation.* 2024;149(6):430–449. PMID [37947085](https://pubmed.ncbi.nlm.nih.gov/37947085/).
4.  Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on CKD outcomes in type 2 diabetes (FIDELIO-DKD). *N Engl J Med.* 2020;383(23):2219–2229. PMID [33264825](https://pubmed.ncbi.nlm.nih.gov/33264825/).
5.  Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on CKD in patients with type 2 diabetes (FLOW). *N Engl J Med.* 2024;391(2):109–121. PMID [38785209](https://pubmed.ncbi.nlm.nih.gov/38785209/).

Andrew Bland, MD, FACP, FAAP · Nephrology Education


---

[Website version](https://urinenephrology.org/2025_UDPA_Lectures_Live/cardiorenal-disease/ckm-syndrome.html) · Markdown synchronized October 3, 2026.